We’re doomed we’re saved mit Andreas Horchler und Louise von Stechow – Vater und Tochter, er Journalist, sie Biologin, sprechen über die Technologien der Biorevolution. Können Gentechnik, Synthetische Biologie und Künstliche Intelligenz die Menschheit vor Krankheit, Klimawandel und Überbevölkerung retten, oder sind diese Technologien der erste Schritt ihres Untergangs? Mehr unter https://science-tales.com/ Inhalt und Bearbeitung: Louise von Stechow und Andreas Horchler Bild: Kelly Sikkema via Unsplash
Cell rejuvenation – Resetting the biological clock
Aging is a dynamic process characterized by the accumulation of cell damage, tissue, and organ degeneration, and diminished function. This process of decline appears to be an inevitable aspect of human existence. In recent years, however, advancements in scientific understanding of aging bring us closer to extending the human lifespan. With their guests, Prof. Jürgen Reess and Prof. Hartmut Geiger, founders of Moglingbio, Louise von Stechow and Andreas Horchler explore the complex science underlying the process of aging and the challenges faced by the budding longevity industry. They talk about the potential for rejuvenating aged cells in human tissues and the ethical considerations of extending the human lifespan. Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast. Image: Marcelo Leal via Unsplash References: Theories and Hallmarks of Aging 1. https://www.afar.org/imported/AFAR_INFOAGING_GUIDE_THEORIES_OF_AGING_2016.pdf 2. https://www.nature.com/scitable/knowledge/library/the-evolution-of-aging-23651151/ 3. https://www.nature.com/articles/s41576-022-00513-5 4. https://www.cell.com/fulltext/S0092-8674(13)00645-4 5. https://www.nature.com/articles/s43587-022-00335-4 6. https://www.nytimes.com/2021/04/27/magazine/global-life-span.html Life-prolonging treatments and Cell Rejuvenation 1. https://www.science.org/content/article/feature-man-who-wants-beat-back-aging 2. https://www.nature.com/articles/s43587-023-00416-y 3. https://www.nature.com/articles/s41586-021-04282-9 4. https://dogagingproject.org/triad 5. https://www.dvcstem.com/post/anti-aging-stem-cells 6. https://www.mayoclinic.org/tests-procedures/bone-marrow-transplant/in-depth/stem-cells/art-20048117 7. https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies 8. https://pubmed.ncbi.nlm.nih.gov/27286740/ 9. https://www.nature.com/articles/s41392-023-01343-5 10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023768/ 11. https://pubmed.ncbi.nlm.nih.gov/35859206/ 12. https://www.nature.com/articles/s41536-022-00275-y 13. https://www.nature.com/articles/s43587-023-00528-5 14. https://www.nature.com/articles/s41591-022-01923-y 15. https://www.nature.com/articles/s43587-023-00373-6 The longevity industry 1. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/longevity-science.html 2. https://www.forbes.com/sites/forbestechcouncil/2021/05/03/will-you-live-to-200-five-levels-of-breakthroughs-in-longevity-research-you-must-know-about/ 3. https://www.theguardian.com/books/2022/may/02/could-we-make-aging-a-thing-of-the-past 4. https://longevity.technology/news/unity-cuts-lead-program-after-clinical-trial-fail/ 5. https://longevity.technology/news/global-longevity-investment-hit-5-2-billion-in-2022/ 6. https://www.nature.com/articles/d41587-022-00002-4 7. https://www.forbes.com/sites/alexzhavoronkov/2023/09/16/what-is-a-longevity-biotechnology-company/?sh=4d4ac9a7702a 8. https://venturebeat.com/business/the-brains-behind-calico-bill-maris-of-google-ventures/ 9. https://spannr.com/articles/longevity-industry-introduction#:~:text=What%20is%20the%20longevity%20industry%3F%20The%20longevity%20industry,promote%20healthy%20aging%20and%20improve%20quality%20of%20life. 10. https://edition.cnn.com/2013/10/03/tech/innovation/google-calico-aging-death/index.html
Erschienen: 03.04.2024
Dauer: 00:43:12
Weitere Informationen zur Episode "We are doomed we are saved #21"
Women’s Health - Humanity’s other half
Women make up about half of humanity. Yet, the medical community and the pharmaceutical and biotech industries have long adopted an androcentric view of disease biology and healthcare needs, perceiving women as a specialized or atypical demographic—outliers. In episode 20 of "We're Doomed, We're Saved," we talk to two biotech experts, Catenion's Dr. Ana Rita Da Costa and Dr. Pascal Joly, to discuss how the biotech industry and healthcare community slowly, but steadily, change and adapt to the needs of half of their customers: women.
Erschienen: 04.03.2024
Dauer: 00:37:33
Weitere Informationen zur Episode "We are doomed we are saved #20"
mRNA Therapeutics - New applications for an old molecule
RNA, one of the oldest and most versatile biomolecules, has recently entered the therapeutic arena. While for many observers the success of mRNA vaccines seemed to come out of the blue, its build on the fundament of research that has large gone ignored. Now mRNA therapeutics are enjoying the limelight of great economic success for companies like BioNTech / Pfizer and Moderna, and the awarding of the 2023 Nobel Prize to two mRNA researchers. But with the fame also comes a huge public backlash of anti-vaxxers who fear the perceived novelty of mRNAs. In the 19th episode of We're doomed, we're saved Louise von Stechow and Andreas Horchler talk with their guest, mRNA researcher Lucia Lapazio who has known the field before and after the hype.
Erschienen: 01.02.2024
Dauer: 00:41:13
Weitere Informationen zur Episode "We are doomed we are saved #19"
Ozempic & co – a new era of weight loss?
In principle the solution to the problem of overweight should be very easy:eat less and exercise more.But anyone who’s ever tried to lose weight – so probably almost anyone – will be able to testify that things are not as simple. So now Ozempic enters the scene, a diabetes drug that looks like a gamechanger in the big business of weight loss. In episode 18 of We're doomed we're saved, Andreas Horchler and Louise von Stechow discuss the history of weight loss pills and the medical and cultural reasons why we (think we) need to be thin.
Erschienen: 02.01.2024
Dauer: 00:34:37
Weitere Informationen zur Episode "We are doomed we are saved #18"
CRISPR CAS – Life’s processing tool
Gene editing technology allows humans, for the first time, to change the code of life with a precise editing system offering the potential for curing genetic diseases. The gene editing field is moving with impressive speed: after the seminal paper on the technology was published in 2012, the Nobel Prize awarded for the technology in 2020, and the first therapy approved for treatment of blood diseases in 2023. In this episode of We’re doomed, we’re saved Andreas Horchler and Louise von Stechow, discuss the tremendous potential of the technology, but also its darker side – the high cost of the therapeutic applications and the potential for augmenting, altering, and redesigning human genomes.
Erschienen: 01.12.2023
Dauer: 00:41:23
Weitere Informationen zur Episode "We are doomed we are saved #17"
Synthetic Biology - Rewriting Life
Erschienen: 01.11.2023
Dauer: 00:40:36
Weitere Informationen zur Episode "We are doomed we are saved #16"
Big Data in Pharma - From Garbage to Gold
In our data-heavy age, data becomes a treasure, a currency, a valuable good. This is true especially for the biotech and pharmaceutical industries, where data can inform the development of novel drugs. But should own biomedical data – and where should the lines between privacy and patient benefit be drawn? In the new episode of We’re doomed, we’re saved, Andreas Horchler and Louise von Stechow discuss new strategies of data sharing and ownership in biomedicine and pharma.
Erschienen: 02.10.2023
Dauer: 00:33:25
Weitere Informationen zur Episode "We are doomed we are saved #15"
De-extinction - A mammoth project
The rapid spread of humans is causing many species to disappear off the face of the earth – in a so-called mass extinction. Some scientists are trying to reverse this process, by bringing back extinct species, such as the Dodo, the Passenger Pigeon, or the Wolly Mammoth. In the 14th episode of We’re doomed, we’re saved Andreas Horchler and Louise von Stechow discuss the breeding procedures and genetic engineering techniques that might be used for brining back extinct animals. We also discuss the ethical implications from resource waste to animal welfare – and what it might mean to be the first and the last member of a (de)extinct species.
Erschienen: 04.09.2023
Dauer: 00:35:07
Weitere Informationen zur Episode "We are doomed we are saved #14"
365 days We´re doomed we´re saved
Ein Jahr We're doomed we're saved - seiten einem Jahr sprechen Andreas Horchler und Louise von Stechow über die Themen der Biorevolution. Wir haben über Anitbiotikaresistenzen, Biowaffen, Gentherapien, Neuroprothesen und AI gesprochen. Wir hatten spannende Gäste, wie den Mathematiker und idalab Gründer Paul von Bünau, und den Forschungs- und Entwicklungschef von Sanofi Adventis Deutschland mit denen wir über die Rolle neuer Technologien wie AI für die Medikamentenentwicklung gesprochen haben. In dieser Folge lassen wir die erste Staffel Revue passieren und machen "A big announcment". Dies wird unsere vorerst letzte Deutsche Episode sein - in der neuen Staffel, ab September, werden wir uns auf Englisch unterhalten.
Erschienen: 02.08.2023
Dauer: 00:25:36
Weitere Informationen zur Episode "We're doomed we're saved #13"
Follow the money - Die Geldquellen der Biowissenschaften
Follow the money, folge dem Geld, ist eine alte Weisheit wenn man den Kern einer Angelegenheit verstehen will. In der 12. Folge von We're doomed we're saved folgen wir diesem Weg zu den Geldquellen der Biomedizinischen Forschung, zu Regierungszuschüssen, großen Pharmaunternehmen und privaten Stiftungen, wie der Bill und Melinda Gates Foundation, die ganze Forschungszweige quasi im Alleingang finanziert. Solche privaten Geldgeber haben besonders in den USA einen großen Einfluss auf die Forschungslandschaft, obwohl ihre Auswahlkriterien und Transparenz umstritten sind und die Verbindung von Wissenschaftlern und reichen Technokraten das Vertrauen in die Wissenschaft verringern kann. Von und mit Andreas Horchler und Louise von Stechow
Erschienen: 03.07.2023
Dauer: 00:33:09
Weitere Informationen zur Episode "We're doomed we're saved #12"
